| Naomi Lam, | |
|
15249 Se Pioneer Dr, Clackamas, OR 97015-7316 | |
| (503) 481-0841 | |
| Not Available |
| Full Name | Naomi Lam |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 15249 Se Pioneer Dr, Clackamas, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023684305 | NPI | - | NPPES |
| CON-0000029 | Other | OR | CONSULTING/DRUGLESS PHARMACY REGISTRATION NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH-0013330 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Naomi Lam, 15249 Se Pioneer Dr, Clackamas, OR 97015-7316 Ph: (503) 481-0841 | Naomi Lam, 15249 Se Pioneer Dr, Clackamas, OR 97015-7316 Ph: (503) 481-0841 |
News Archive
TransPerfect and Sentrx have announced a collaboration involving TransPerfect's Trial Interactive Portal Technology, which will streamline end-to-end global drug safety capabilities in both clinical and post-marketing event management.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).
According to news outlets, the report focused on the care of patients with disabilities, and steps to make sure anti-fraud efforts don't add to states' burdens.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
› Verified 4 days ago
Amanda Whitecotten, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12002 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-698-8446 Fax: 503-698-5020 | |
Julia Han, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-517-4665 | |
Dr. Karyn Nafey, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16300 Se Evelyn St, Clackamas, OR 97015 Phone: 503-305-9700 | |
Thanh Van Hoang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9800 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-571-8879 | |
Hannah Larsen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9800 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-571-8879 | |
Flora Yong, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16300 Se Evelyn St, Clackamas, OR 97015 Phone: 503-656-1461 |